ARIZ PRECISION MEDICINE IS USING INNOVATIVE TECHNOLOGIES TO DEVELOP DRUGS FOR CANCER THERAPY
Cancer impacts every person on Earth: By treating cancer at the root cause, ARIZ is designing products that will safely, effectively and selectively induce programmed cell death in cancer cells.
As depicted in the ARIZ logo above, ARIZ is developing targeted drug delivery systems that can deliver new types of drugs that preferentially enter into cancer cells and cause cancer cell death.
To effectively and safely treat cancer or cure cancer:
- Drugs must be developed that eliminate the cause, block cancer cell spread and recurrence.
- Drugs must reach the cancer cell in high concentrations and avoid normal cells.
- Drugs must enter the cancer cells & kill them at the right time, early in development of cancer.
To accomplish this, ARIZ Precision Medicine has designed, developed and/or acquired:
- Unique drugs that block bad DNA from making cancer cells, kills cancer cells and block metastasis
- Customized Drug Delivery Systems that ensure the right drug to the right place at the right time
To destroy cancer cells early, ARIZ is using:
- Biomarkers, such as certain proteins easily detected in the blood or urine, that guide product development, help to personalize cancer therapy & monitor therapy
- Biomarkers that simplify clinical trials in humans and reduce the time, costs and adverse effects, while boosting the overall effectiveness of ARIZ drug candidates.
ARIZ PRECISION MEDICINE JOINS THE 'DRIVE' PROGRAM AT UNIVERSITY OF CALIFORNIA, DAVIS
On February 15, 2016 an announcement was made about the start up of the ARIZ research lab at UC Davis.
- This lab will conduct Proof of Principle studies and provide scientific data in support of provisional and non-provisional patent applications that cover ARIZ product candidates.
- The ARIZ lab will be collaborating with the lab of Dr. Kit Lam, Hematologist/Oncologist and Chairman of Biochemistry and Molecular Biology at UC Davis. Dr. Lam is a scientific and medical advisor to ARIZ.
 American Cancer Society, 2016